

# Provider View



## ProviderView – November 21, 2023

### Changes to Avera Health Plans' Humira™ Coverage

Providing access to safe and effective medications at the lowest available cost is Avera Health Plans' top priority when making medication policy decisions. With the emergence of nine adalimumab biosimilar products, Avera Health Plans Pharmacy Services department has been working diligently with key stakeholders to determine the best adalimumab strategy.

Effective November 9, 2023, Humira™ will move to a non-preferred status on all formularies. Adalimumab-adaz HC (high concentration) and Hadlima™ HC (adalimumab-bwwd) will be placed in a preferred status. Preferred products offer patients with autoimmune diseases a more cost effective adalimumab option while maintaining the same clinical benefits as Humira™.

If Humira™ is requested for a patient who is new to therapy or on existing therapy, the requesting provider will receive a letter indicating the approval of both preferred adalimumab products and the denial Humira™ if preauthorization criteria is met. Biosimilar manufacturers have indicated that patient financial assistance will be available for those unable to afford their medications. Patients should inquire with their dispensing pharmacy.

From all of the staff at Avera Health Plans, we wish you all a Happy Thanksgiving Holiday.